Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate
Autor: | Meni Girshengorn, Ofir Israeli, Lilach Cherry, Edith Lupu, Arnon Tal, Rona Levy, Osnat Rosen, Arik Monash, Einat Toister, Yaron Kafri, Arik Makovitzki, Lilach Levin, Irit Simon, Eyal Dor, Ziv Oren, Elad Lerer, Idan Hefetz, Hanan Tzadok, Yaakov Adar, Eyal Epstein, Ophir Hazan |
---|---|
Rok vydání: | 2021 |
Předmět: |
PES
polyethersulfone rVSV-S recombinant vesicular stomatitis virus-ΔG-spike COVID-19 Vaccines MWCO molecular weight cutoff Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PFU plaque-forming units TMP transmembrane pressure ACE2 angiotensin-converting enzyme 2 DSP downstream process Article MEM minimal essential medium HF-TFF hollow fiber-tangential flow filtration Downstream (manufacturing) rVSV SFM serum-free medium Animals Humans hc-DNA host cell DNA DO dissolved oxygen Pandemics Infectivity MOI multiplicities of infection Downstream process General Veterinary General Immunology and Microbiology Chemistry SARS-CoV-2 Public Health Environmental and Occupational Health Spike Protein COVID-19 Endonuclease digestion Antibodies Neutralizing Cell biology Clarification MT multi-tray Infectious Diseases Recombinant viral vaccine Cell culture Spike Glycoprotein Coronavirus Nucleic acid Molecular Medicine Hollow fiber HCP host cell protein NTU nephelometric turbidity units HR horseradish peroxidase |
Zdroj: | Vaccine |
ISSN: | 1873-2518 |
Popis: | rVSV-Spike (rVSV-S) is a recombinant viral vaccine candidate under development to control the COVID-19 pandemic and is currently in phase II clinical trials. rVSV-S induces neutralizing antibodies and protects against SARS-CoV-2 infection in animal models. Bringing rVSV-S to clinical trials required the development of a scalable downstream process for the production of rVSV-S that can meet regulatory guidelines. The objective of this study was the development of the first downstream unit operations for cell-culture-derived rVSV-S, namely, the removal of nucleic acid contamination, the clarification and concentration of viral harvested supernatant, and buffer exchange. Retaining the infectivity of the rVSV-S during the downstream process was challenged by the shear sensitivity of the enveloped rVSV-S and its membrane protruding spike protein. Through a series of screening experiments, we evaluated and established the required endonuclease treatment conditions, filter train composition, and hollow fiber-tangential flow filtration parameters to remove large particles, reduce the load of impurities, and concentrate and exchange the buffer while retaining rVSV-S infectivity. The combined effect of the first unit operations on viral recovery and the removal of critical impurities was examined during scale-up experiments. Overall, approximately 40% of viral recovery was obtained and the regulatory requirements of less than 10 ng host cell DNA per dose were met. However, while 86–97% of the host cell proteins were removed, the regulatory acceptable HCP levels were not achieved, requiring subsequent purification and polishing steps. The results we obtained during the scale-up experiments were similar to those obtained during the screening experiments, indicating the scalability of the process. The findings of this study set the foundation for the development of a complete downstream manufacturing process, requiring subsequent purification and polishing unit operations for clinical preparations of rVSV-S. |
Databáze: | OpenAIRE |
Externí odkaz: |